Skip to content
    Reviews

    PD-1/PD-L1 Inhibitors With Chemotherapy Prolong Survival in Cervical Cancer

    Luo et alFrontiers in immunology

    PD-1/PD-L1 Inhibitors With Chemotherapy Prolong Survival in Cervical Cancer
    A systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated the clinical efficacy and safety of adding PD-1/PD-L1 inhibitors to chemotherapy with or without bevacizumab for recurrent or metastatic cervical cancer. Searches were conducted across PubMed, Embase, Web of Science, Cochrane Library, Scopus, and ClinicalTrials.gov for RCTs published up to January 14, 2026. The primary outcomes assessed were overall survival (OS) and progression-free survival (PFS), with hazard ratios derived from reconstructed Kaplan-Meier curves.
    The analysis included six RCTs involving 2,242 patients, of whom 1,131 received PD-1/PD-L1 inhibitors plus chemotherapy ± bevacizumab and 1,111 received chemotherapy ± bevacizumab alone. The combination regimen significantly prolonged median OS (28.7 months vs. 19.4 months) and median PFS (12.0 months vs. 8.7 months). Pooled risk ratios (RRs) for tumor response were 1.235 (95% CI, 1.153–1.322) for objective response rate, 1.606 (95% CI, 1.333–1.936) for complete response, 1.127 (95% CI, 0.994–1.277) for partial response, 0.733 (95% CI, 0.612–0.878) for stable disease, and 0.460 (95% CI, 0.305–0.695) for progressive disease.
    Regarding safety, the risk of any-grade adverse events did not differ significantly between treatment groups (RR 0.999, 95% CI, 0.991–1.008). However, the combination was associated with an increased risk of grade ≥3 adverse events (RR 1.069, 95% CI, 1.019–1.121). Frequently reported adverse reactions included nausea, anemia, constipation, arthralgia, neutropenia, hypertension, alopecia, and peripheral neuropathy. The authors concluded that adding PD-1/PD-L1 inhibitors to chemotherapy ± bevacizumab significantly improves OS and PFS in recurrent or metastatic cervical cancer, alongside a modest increase in high-grade toxicity.

    Key Takeaways

    • The addition of PD-1/PD-L1 inhibitors to chemotherapy ± bevacizumab significantly prolonged median overall survival (28.7 vs. 19.4 months) and median progression-free survival (12.0 vs. 8.7 months) compared with chemotherapy ± bevacizumab alone.
    • Combination therapy yielded pooled risk ratios of 1.235 (95% CI, 1.153–1.322) for objective response rate, 1.606 (95% CI, 1.333–1.936) for complete response, and 0.460 (95% CI, 0.305–0.695) for progressive disease.
    • The risk of any-grade adverse events did not differ significantly between arms (RR 0.999, 95% CI 0.991–1.008), but the combination regimen was associated with an increased risk of grade ≥3 adverse events (RR 1.069, 95% CI 1.019–1.121).
    Read the original sourceFrontiers in immunology